{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=14&state=Washington",
    "query": {
      "state": "Washington",
      "city": "Seattle",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 11398,
    "total_pages": 1140,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=15&state=Washington&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=13&state=Washington&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T12:28:21.065Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00346359",
      "title": "Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2006-03",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346359"
    },
    {
      "nct_id": "NCT05819359",
      "title": "Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "BIA 28-6156 10 mg",
          "type": "DRUG"
        },
        {
          "name": "BIA 28-6156 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bial R&D Investments, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 237,
      "start_date": "2023-03-31",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 43,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05819359"
    },
    {
      "nct_id": "NCT03997344",
      "title": "Veterans Nature Therapy (Vet Hike)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Posttraumatic Stress Disorders"
      ],
      "interventions": [
        {
          "name": "Group nature hikes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Group urban hikes",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-05-10",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997344"
    },
    {
      "nct_id": "NCT06735209",
      "title": "First-in-Human PfSPZ-LARC2 Vaccination/CHMI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ (7G8) Challenge",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 22,
      "start_date": "2025-07-23",
      "completion_date": "2026-07-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06735209"
    },
    {
      "nct_id": "NCT02927067",
      "title": "A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytomegalovirus (CMV)"
      ],
      "interventions": [
        {
          "name": "Maribavir",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 553,
      "start_date": "2017-04-14",
      "completion_date": "2022-07-01",
      "has_results": true,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927067"
    },
    {
      "nct_id": "NCT00483444",
      "title": "Telephone Follow-Up on Outcome After Mild Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Concussion"
      ],
      "interventions": [
        {
          "name": "Scheduled telephone follow-up",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 366,
      "start_date": "2003-10",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483444"
    },
    {
      "nct_id": "NCT03578887",
      "title": "A Cohort Study of Weight Loss and Gliosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity, Gliosis, Weight-Loss"
      ],
      "interventions": [
        {
          "name": "Behavioral Weight Loss Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Roux-en-Y Gastric Bypass or Sleeve Gastrectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "25 Years to 64 Years"
      },
      "enrollment_count": 112,
      "start_date": "2019-06-01",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578887"
    },
    {
      "nct_id": "NCT00496860",
      "title": "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Metastatic Malignancies"
      ],
      "interventions": [
        {
          "name": "ALT-801",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2007-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496860"
    },
    {
      "nct_id": "NCT02296580",
      "title": "A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Nativis Voyager RFE Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Nativis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-02",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296580"
    },
    {
      "nct_id": "NCT06136559",
      "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nemtabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2023-12-13",
      "completion_date": "2032-09-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-02T12:28:21.065Z",
      "location_count": 49,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06136559"
    }
  ]
}